---
title: "Editorial Note: Retractions linked to Naringenin–MCF-7 study cited in PLOS ONE article"
id: "plos-one-12-editorial-note-naringenin-impairs-mitochondrial-function-via-ros-to-induce"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-12-editorial-note-naringenin-impairs-mitochondrial-function-via-ros-to-induce"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362926"
published_at: "2026-11-17T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Editorial Note: Retractions linked to Naringenin–MCF-7 study cited in PLOS ONE article
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-12-editorial-note-naringenin-impairs-mitochondrial-function-via-ros-to-induce
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362926)
- **Published At:** 2026-11-17T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The PLOS One Editors published an Editorial Note regarding a 2025 research article titled “Naringenin impairs mitochondrial function via ROS to induce apoptosis in tamoxifen resistant MCF-7 breast cancer cells.” - The note identifies two references in the article’s bibliography that were retracted: Reference 23 was retracted after the article’s publication, and Reference 52 had been retracted prior to publication. The Editorial Note does not list the contents or authors of those retracted references. - The editors stated that, in their assessment, the two retracted references are not essential to support the research findings or the conclusions reported in the 2025 article. - The Editorial Note provides bibliographic metadata for the original article: authorship attributed to Eanes LA, Eldeeb M, Storholt D, Patel YM; journal PLoS One; citation details as reported by PLOS; and a CrossRef DOI linking to the original article record. - The Editorial Note itself was published November 17, 2026, and is open access under a Creative Commons Attribution license; it points readers to the original PLoS One article page and associated resources (PDF, metrics, comments). - The note does not provide additional experimental data, methodological clarifications, or corrections to the study’s results; it is limited to informing readers about the status of the two referenced works and the editors’ judgment about their relevance. - Readers seeking further detail are referred to the original article record and linked resources; the Editorial Note functions as an informational flag rather than a formal correction or expression of concern.
## Clinical Analysis & Structured Key Points
[ Skip to main content ](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362926#main-content) Advertisement * [plos.org](https://plos.org/) * [Create account](https://community.plos.org/registration/new) * [Sign in](https://journals.plos.org/user/secure/login?page=%2Fplosone%2Farticle%3Fid%3D10.1371%2Fjournal.pone.0362926) * * About * Browse * Publish * [](https://journals.plos.org/plosone/ "PLOS One") * Search [advanced search](https://journals.plos.org/plosone/search) * [Browse Topics](https://journals.plos.org/plosone/subjectAreaBrowse) Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click [here](https://github.com/PLOS/plos-thesaurus/blob/master/README.md "Link opens in new window"). [](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362926) [](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362926) * 0 [Save](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362926#savedHeader) [Total Mendeley and Citeulike bookmarks.](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362926#savedHeader) * 0 [Citation](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362926#citedHeader) [Paper's citation count computed by Dimensions.](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362926#citedHeader) * 40 [View](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362926#viewedHeader) [PLOS views and downloads.](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362926#viewedHeader) * 0 [Share](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362926#discussedHeader) [Sum of Facebook, Twitter, Reddit and Wikipedia activity.](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362926#discussedHeader) Open Access Editorial Note Editorial Notes are published by PLOS to provide readers information relevant to an article’s interpretation. [See all article types » ](https://journals.plos.org/plosone/s/other-article-types) # Editorial Note: Naringenin impairs mitochondrial function via ROS to induce apoptosis in tamoxifen resistant MCF-7 breast cancer cells * The PLOS One Editors # Editorial Note: Naringenin impairs mitochondrial function via ROS to induce apoptosis in tamoxifen resistant MCF-7 breast cancer cells * The PLOS One Editors ![PLOS](https://journals.plos.org/resource/img/logo-plos-full-color.svg) x * Published: November 17, 2026 * * [Article](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362926) * [Metrics](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362926) * [Comments](https://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0362926) * [Media Coverage](http://plos.altmetric.com/details/doi/10.1371/journal.pone.0362926) * [Reference](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362926#reference) * [Reader Comments](https://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0362926) The _PLOS One_ Editors issue this Editorial Note to inform readers of the following issues that were noted after this article’s [[1](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362926#pone.0362926.ref001)] publication: * Reference 23 was retracted after [[1](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362926#pone.0362926.ref001)] was published. * Reference 52 was retracted before [[1](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362926#pone.0362926.ref001)] was published. PLOS considers that these references are not crucial in supporting the research or conclusions reported in [[1](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362926#pone.0362926.ref001)]. ## Reference 1. 1. Eanes LA, Eldeeb M, Storholt D, Patel YM. Naringenin impairs mitochondrial function via ROS to induce apoptosis in tamoxifen resistant MCF-7 breast cancer cells. PLoS One. 2025;20(4):e0320020. pmid:40179084 * [ View Article ](https://doi.org/10.1371/journal.pone.0320020 "Go to article") * [ PubMed/NCBI ](http://www.ncbi.nlm.nih.gov/pubmed/40179084 "Go to article in PubMed") * [ Google Scholar ](http://scholar.google.com/scholar?q=Naringenin+impairs+mitochondrial+function+via+ROS+to+induce+apoptosis+in+tamoxifen+resistant+MCF-7+breast+cancer+cells+Eanes+2025 "Go to article in Google Scholar") **Citation:** The _PLOS One_ Editors (2026) Editorial Note: Naringenin impairs mitochondrial function via ROS to induce apoptosis in tamoxifen resistant MCF-7 breast cancer cells. PLoS One 21(11): e0362926. https://doi.org/10.1371/journal.pone.0362926 **Published:** November 17, 2026 **Copyright:** © 2026 The PLOS One Editors. This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. [Download PDF](https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0362926&type=printable) * [Citation](https://journals.plos.org/plosone/article/citation?id=10.1371/journal.pone.0362926) * [XML](https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0362926&type=manuscript) [Print](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362926) Share * [![Reddit](https://journals.plos.org/resource/img/icon.reddit.16.png)Reddit](https://www.reddit.com/submit?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0362926 "Submit to Reddit") * [![Facebook](https://journals.plos.org/resource/img/icon.fb.16.png)Facebook](https://www.facebook.com/share.php?u=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0362926&t=Editorial%20Note:%20Naringenin%20impairs%20mitochondrial%20function%20via%20ROS%20to%20induce%20apoptosis%20in%20tamoxifen%20resistant%20MCF-7%20breast%20cancer%20cells "Share on Facebook") * [![LinkedIn](https://journals.plos.org/resource/img/icon.linkedin.16.png)LinkedIn](https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0362926&title=Editorial%20Note:%20Naringenin%20impairs%20mitochondrial%20function%20via%20ROS%20to%20induce%20apoptosis%20in%20tamoxifen%20resistant%20MCF-7%20breast%20cancer%20cells&summary=Checkout%20this%20article%20I%20found%20at%20PLOS "Add to LinkedIn") * [![Mendeley](https://journals.plos.org/resource/img/icon.mendeley.16.png)Mendeley](https://www.mendeley.com/import/?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0362926 "Add to Mendeley") * [![Bluesky](https://journals.plos.org/resource/img/icon.bluesky.light.png)Bluesky](https://bsky.app/intent/compose?text=Checkout%20this%20article%20I%20found%20at%20PLOS:%20https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0362926 "Share on Bluesky") * ![Email](https://journals.plos.org/resource/img/icon.email.16.png)Email ![Check for updates via CrossMark](https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_BW_horizontal.svg) ### Related PLOS Articles * **COMMENTARY pertains to** * Naringenin impairs mitochondrial function via ROS to induce apoptosis in tamoxifen resistant MCF-7 breast cancer cells * [View Page](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0320020) * [PDF](https://journals.plos.org/plosone/article/file?type=printable&id=10.1371/journal.pone.0320020 "PDF opens in new window") Advertisement * [Publications](https://plos.org/our-journals/) * [PLOS Aging and Health](https://journals.plos.org/agingandhealth/) * [PLOS Biology](https://journals.plos.org/plosbiology/) * [PLOS Climate](https://journals.plos.org/climate/) * [PLOS Complex Systems](https://journals.plos.org/complexsystems/) * [PLOS Computational Biology](https://journals.plos.org/ploscompbiol/) * [PLOS Digital Health](https://journals.plos.org/digitalhealth/) * [PLOS Ecosystems](https://journals.plos.org/ecosystems/) * [PLOS Genetics](https://journals.plos.org/plosgenetics/) * [PLOS Global Public Health](https://journals.plos.org/globalpublichealth/) * [PLOS Medicine](https://journals.plos.org/plosmedicine/) * [PLOS Mental Health](https://journals.plos.org/mentalhealth/) * [PLOS Neglected Tropical Diseases](https://journals.plos.org/plosntds/) * [PLOS One](https://journals.plos.org/plosone/) * [PLOS Pathogens](https://journals.plos.org/plospathogens/) * [PLOS Sustainability and Transformation](https://journals.plos.org/sustainabilitytransformation/) * [PLOS Water](https://journals.plos.org/water/) * [Home](https://plos.org) * [Blogs](https://blogs.plos.org) * [Collections](https://collections.plos.org/) * Give feedback * [LOCKSS](https://journals.plos.org/plosone/lockss-manifest) * [Privacy Policy](https://plos.org/privacy-policy) * [Terms of Use](https://plos.org/terms-of-use) * [Advertise](https://plos.org/advertise/) * [Media Inquiries](https://plos.org/media-inquiries) * [Contact](https://plos.org/contact) ![PLOS](https://journals.plos.org/resource/img/logo-plos-footer.png) PLOS is a nonprofit 501(c)(3) corporation, #C2354500, based in California, US ![PLOS Logo](data:image/svg+xml;charset=utf-8;base64,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) ### Cookie Preference Center Our website uses different types of cookies. Optional cookies will only be set with your consent and you may withdraw this consent at any time. Below you can learn more about the types of cookies PLOS uses and register your cookie preferences. Accept All Cookies ### Customize Your Cookie Preference +**Strictly Necessary** Always On +**Functional** OnOff +**Performance and Analytics** OnOff +**Marketing** OnOff Save Selected Preferences and Close [For more information about the cookies and other technologies used by us, please read our Cookie Policy.](https://plos.org/cookies-policy)
## Related Clinical Research

- [Proprioceptive Neuromuscular Facilitation for Upper-Limb Rehab After Breast Cancer: Systematic Rev](https://medichelpline.com/clinical-feed/pubmed-43064868.md) (DOI: 10.1007/s11912-026-01867-3)
- [hsa‑circ‑0007766 drives breast cancer cell growth and spread via a miR‑1301‑3p/DNMT3B feedback loop](https://medichelpline.com/clinical-feed/pubmed-43059377.md) (DOI: 10.3892/mmr.2026.14078)
- [Circulating immune signatures during pembrolizumab-based neoadjuvant therapy in early triple-negat](https://medichelpline.com/clinical-feed/medrxiv-21-circulating-immune-dynamics-during-neoadjuvant-chemoimmunotherapy-in-early.md)
- [FDA clears Roche’s giredestrant; semaglutide shows efficacy in children with severe obesity](https://medichelpline.com/clinical-feed/stat-news-4-stat-pharmalittle-we-re-reading-about-a-roche-breast-cancer-pill-obesity-drugs.md)
- [Breast cancer survival prediction using HEAL-Surv multimodal distillation](https://medichelpline.com/clinical-feed/medrxiv-15-hierarchical-graph-learning-with-multimodal-distillation-for-breast-cancer.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.